[1] Spadaro M, Winklmeier S, Beltrán E, Macrini C, Höftberger R, Schuh E, Thaler FS, Gerdes LA, Laurent S, Gerhards R, Brändle S, Dornmair K, Breithaupt C, Krumbholz M, Moser M, Krishnamoorthy G, Kamp F, Jenne D, Hohlfeld R, Kümpfel T, Lassmann H, Kawakami N, Meinl E. Pathogenicity of human antibodies against myelin oligodendrocyte glycoprotein[J]. Ann Neurol, 2018, 84:315-328.
[2] Ramanathan S, Dale RC, Brilot F. Anti-MOG antibody:the history, clinical phenotype, and pathogenicity of a serum biomarker for demyelination[J]. Autoimmun Rev, 2016, 15:307-324.
[3] Jarius S, Paul F, Aktas O, Asgari N, Dale RC, de Seze J, Franciotta D, Fujihara K, Jacob A, Kim HJ, Kleiter I, Kümpfel T, Levy M, Palace J, Ruprecht K, Saiz A, Trebst C, Weinshenker BG, Wildemann B. MOG encephalomyelitis:international recommendations on diagnosis and antibody testing[J]. J Neuroinflammation, 2018, 15:134.
[4] Chen L, Chen C, Zhong X, Sun X, Zhu H, Li X, Yang H, Shu Y, Chang Y, Hu X, Lu X, Peng L, Qiu W. Different features between pediatric-onset and adult-onset patients who are seropositive for MOG-IgG:a multicenter study in South China[J]. J Neuroimmunol, 2018, 321:83-91.
[5] Ogawa R, Nakashima I, Takahashi T, Kaneko K, Akaishi T, Takai Y, Sato DK, Nishiyama S, Misu T, Kuroda H, Aoki M, Fujihara K. MOG antibody-positive, benign, unilateral, cerebral cortical encephalitis with epilepsy[J]. Neurol Neuroimmunol Neuroinflamm, 2017, 4:e322.
[6] Salama S, Khan M, Pardo S, Izbudak I, Levy M. MOG antibody-associated encephalomyelitis/encephalitis[J]. 2019, 25:1427-1433.
[7] Zhou L, Bao JZ, Li H, Li X, Huang Y, Wang M, Zhao C, Lu J, Lu C, Li Y, Quan C. Cerebral cortical encephalitis followed by recurrent CNS demyelination in a patient with concomitant anti-MOG and anti-NMDA receptor antibodies[J]. Mult Scler Relat Disord, 2017, 18:90-92.
[8] Lipton SA. NMDA receptors, glial cells, and clinical medicine[J]. Neuron, 2006, 50:9-11.
[9] Ren Y, Chen Y, He Q, Wang R, Lu W. Co-occurrence of anti-N-methyl-D-aspartate receptor encephalitis and anti-myelin oligodendrocyte glycoprotein inflammatory demyelinating diseases:a clinical phenomenon to be taken seriously[J]. Front Neurol, 2019, 10:1271.
[10] Sueki H, Mizukawa Y, Aoyama Y. Immune reconstitution inflammatory syndrome in non-HIV immunosuppressed patients[J]. J Dermatol, 2018, 45:3-9.
[11] Guan HZ,Cui LY. Antibody related central nervous system autoimmune diseases:exploration and challenge[J]. Zhonghua Shen Jing Ke Za Zhi, 2019, 52:81-84.[关鸿志, 崔丽英. 抗体相关的中枢神经系统自身免疫性疾病:探索与挑战[J]. 中华神经科杂志, 2019, 52:81-84.]
[12] Hamid SH, Whittam D, Saviour M, Alorainy A, Mutch K, Linaker S, Solomon T, Bhojak M, Woodhall M, Waters P, Appleton R, Duddy M, Jacob A. Seizures and encephalitis in myelin oligodendrocyte glycoprotein IgG disease vs aquaporin 4 IgG disease[J]. JAMA Neurol, 2018, 75:65-71.
[13] Chalmoukou K, Alexopoulos H, Akrivou S, Stathopoulos P, Reindl M, Dalakas MC. Anti-MOG antibodies are frequently associated with steroid-sensitive recurrent optic neuritis[J]. Neurol Neuroimmunol Neuroinflamm, 2015, 2:e131.
[14] Juryńczyk M, Jacob A, Fujihara K, Palace J. Myelin oligodendrocyte glycoprotein (MOG) antibody-associated disease:practical considerations[J]. Pract Neurol, 2019, 19:187-195.
[15] Reindl M, Waters P. Myelin oligodendrocyte glycoprotein antibodies in neurological disease[J]. Nat Rev Neurol, 2019, 15:89-102.